Literature DB >> 7766722

Determination of MK-0476 in human plasma by liquid chromatography.

R D Amin1, H Cheng, J D Rogers.   

Abstract

A simple and accurate assay for quantitating MK-0476 [sodium 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-(E)-(ethenyl)phenyl)(3-(2-(1- hydroxy-1-methylethyl)phenyl)propyl)thio)-methyl)cyclopropane)acetate], which is a potent and selective leukotriene D4-receptor antagonist, in human plasma has been developed. The method involves precipitation of protein and reversed-phase liquid chromatography with fluorescence detection. The assay is linear in the range of 30-3000 ng ml-1 of MK-0476, and the limit of detection is 5 ng ml-1. The interday precision (% relative standard deviation) values of this method at 51 and 2040 ng ml-1 are 10 and 3%, respectively. The interday accuracy values at these concentrations are 94 and 104%, respectively. The absolute recovery of MK-0476 is 99%. The utility of this method to determine plasma concentrations of MK-0476 in humans receiving the drug orally was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7766722     DOI: 10.1016/0731-7085(94)00138-r

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.

Authors:  H Cheng; J A Leff; R Amin; B J Gertz; M De Smet; N Noonan; J D Rogers; W Malbecq; D Meisner; G Somers
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

2.  An automated method for the determination of montelukast in human plasma using dual-column HPLC analysis and peak height summation of the parent compound and its photodegradation product.

Authors:  Glenn A Smith; Cynthia M Rawls; Robert L Kunka
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

3.  A population pharmacokinetic model for montelukast disposition in adults and children.

Authors:  Rohini Ramakrishnan; Elizabeth Migoya; Barbara Knorr
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

4.  Development and Validation of a RP-HPLC Method for Estimation of Montelukast Sodium in Bulk and in Tablet Dosage Form.

Authors:  R M Singh; P K Saini; S C Mathur; G N Singh; B Lal
Journal:  Indian J Pharm Sci       Date:  2010-03       Impact factor: 0.975

5.  Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response.

Authors:  Edward B Mougey; Hua Feng; Mario Castro; Charles G Irvin; John J Lima
Journal:  Pharmacogenet Genomics       Date:  2009-02       Impact factor: 2.089

6.  Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast.

Authors:  Barbara Knorr; Alan Hartford; Xiujiang Susie Li; Amy Yifan Yang; Gertrude Noonan; Elizabeth Migoya
Journal:  Arch Drug Inf       Date:  2010-06

7.  Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.

Authors:  Donald H Arnold; Sara L Van Driest; Theodore F Reiss; Jennifer C King; Wendell S Akers
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126

8.  Development and Validation of a Rapid RP-UPLC Method for the Simultaneous Estimation of Bambuterol Hydrochloride and Montelukast Sodium from Tablets.

Authors:  R Yanamandra; C S Vadla; U M Puppala; B Patro; Y L N Murthy; A R Parimi
Journal:  Indian J Pharm Sci       Date:  2012-03       Impact factor: 0.975

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.